Release Date: September 19, 2012 | Expiration Date: September 19, 2013
Media:  Internet-based

Overview

Prostate cancer is one of the most common cancers in men, affecting 1 out of every 6 men in the US. In 2012, it is estimated that there will be more than 241,000 new cases of prostate cancer with approximately 28,000 resultant deaths. While most advanced/metastatic prostate cancers are sensitive to androgen deprivation therapy, they will eventually progress to the stage of castration-resistance. Traditionally, treatment options for patients with metastatic castration-resistant prostate cancer were limited, with only one chemotherapeutic agent demonstrating a survival benefit in this setting. However, in the past several years a number of new systemic agents have been added to the therapeutic armamentarium based on demonstrated survival advantages.  It is important for clinicians to be aware of these new options, and understand how to use them most effectively, in order to select the most appropriate therapy, or sequence of therapies, for individual patients.

Target Audience

This educational activity is directed toward medical oncologists, urologists, surgical oncologists and radiation oncologists interested in the treatment of patients with prostate cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of prostate cancer may also benefit from this activity.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Assess the efficacy and safety of novel agents for the treatment of metastatic castration-resistant prostate cancer
• Integrate new treatment options in order to individualize therapy and optimize outcomes for patients with metastatic castration-resistant prostate cancer

Instructions For Receiving Credit

In order to receive a CME certificate, participants must complete the pre-test, view any number of the cases, complete the post-test and pass with a score of 70% or higher, complete the evaluation, and request for credit.  Participants may immediately download a CME certificate upon completion of these steps.

Faculty

A. Oliver Sartor, MD
Medical Director, Tulane Cancer Center
Laborde Professor of Cancer Research
Piltz Professor of Urology and Medicine
Tulane University School of Medicine
New Orleans, LA

Medical Writer

Susan R. Peck, PhD

Disclosure Policy/Resolution Of Conflict Of Interest (COI)

As a sponsor accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of PER to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. PER additionally requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that create a COI. All relevant financial relationships with any commercial interests are disclosed to participants prior to the beginning of PER’s CME activities. PER has identified and resolved all COI prior to the start of this activity using a multi-step process.

Disclosure Of Relevant Financial Relationships With Commercial Interests

The following individuals have relevant financial relationships with commercial interests to disclose:
A. Oliver Sartor, MD – Grant/Research:  Algeta, Bayer, and Dendreon; Consultant: Algeta, Bayer, Bavarian‑Nordic, Bellicum, Bristol Myers Squibb, and Dendreon.
 
The following individuals have no relevant financial relationships with commercial interests to disclose:
The staff of Physicians’ Education Resource, LLC: Tristan Nelsen, MNM, CMP and Susan R. Peck, PhD.

Off-Label Disclaimer

This CME activity will contain discussions about off-label/unapproved uses of drugs to treat prostate cancer.  For additional information about approved uses, including approved indications, contraindications, and warnings, participants are advised to consult prescribing information for all products discussed or consult the Physicians’ Desk Reference.
 
The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.

Disclaimer

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource, LLC, or any of the companies that provided commercial support for this CME activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) ¦ Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)

• A Pentium-based PC or compatible computer
• At least 64MB of RAM
• Windows 95/98/NT/ME/2000/XP/Vista system software
• Screen resolution of 1024 x 786 or larger recommended
• PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise

Minimum System Requirements (Mac OS)

• A PowerPC processor-based Macintosh computer
• At least 64MB of RAM
• Mac OS 7.5 or later
• Screen resolution of 1024 x 786 or larger recommended

PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise